Participant flow

Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients · Source last updated 2022-01-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   This was a retrospective sample analysis representative for practices and hospitals in Germany. The treatments and infection data were collected from patients with chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM). GL adherence (GLAD) was analysed.

   id

   FG000

   title

   Not Applicable. Non-interventional Retropspective Observational Study.

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         1086

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         1086

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The time period was chosen to ensure that patients have been followed up for at least 12 months in order to collect data on susceptibility to infection and possible secondary immunodeficiencies

recruitment Details

This is a retrospective sample analysis of patients from practices and hospitals in Germany who were representatively screened using previously collected care parameters of the participating institutions. Previous and current treatment and infection data were collected from patients who received a line of therapy for the treatment of CLL or MM started in 2018 (1st, 2nd and 3rd or higher line).

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice